Repligen Corporation (NASDAQ:RGEN) Q3 2023 Earnings Call Transcript

Operator: Thank you. And the next question comes from Brandon Couillard with Jefferies.

Brandon Couillard: Good morning. Jason talked about some SKU rationalization planned. Can you just touch on which segments that will affect and whether it’ll be a headwind to revenues? I imagine that’s not for programs that are already commercial, but any more color and share on that? Thanks.

Jason Garland: Yes. Brandon, it’s really just focused on the COVID related business that we had. So it’s at a SKU level that we’re either it was COVID or demand is no longer there, so nothing that affects any go forward from a base business perspective.

Brandon Couillard: Mainly filtration. Okay. And Tony, what do you expect to cell and gene therapy customer base to do in terms of revenue growth in 2023 now? I think that had been flat. I’m just curious if that changed.

Tony Hunt: I think – and I don’t have the exact number, but I would say, it’s probably flat year-on-year, which is not bad considering the rest of the market’s been this year.

Operator: Thank you. And this concludes our question-and-answer session. I would like to return the conference over to Tony Hunt for any closing comments.

Tony Hunt: Great. Thanks everybody for joining us. Look forward to chatting with everybody in a few months time and hopefully close out 2023 and talk about improvements in 2024. So look forward to catching up then. Thank you guys.

Operator: Thank you. The conference has now concluded. Thank you for attending. Today’s presentation. You may now disconnect your lines.